B-Cell Targeting Is Creating New Opportunities Across Immunology
The market is estimated to grow from approximately USD 21.2 billion in 2025 to USD 24.6 billion in 2026 and USD 51.5 billion by 2035, representing a CAGR of around 8.6%.
More than 400 B-cell inhibitors are currently being evaluated across different stages of development. While marketed therapies account for the majority of current revenues, the clinical pipeline remains active, with Phase II and Phase III programs representing substantial portions of development activity.
https://www.rootsanalysis.com/....reports/b-cell-inhib
پسندیدن
اظهار نظر
اشتراک گذاری
